down arrow

Reviva Pharmaceuticals Holdings, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US76152G1004
USD
0.59
0.04 (6.43%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.590.62

52 Week

0.254.28
Valuation
Technical
Day's Volume

CASH

421.8 k

Shareholding (Mar 2025)

FII

2.49%

Held by 17 FIIs

DII

92.62%

Held by 6 DIIs

Promoter

0.00%

How big is Reviva Pharmaceuticals Holdings, Inc.?

22-Jun-2025

As of Jun 18, Reviva Pharmaceuticals Holdings, Inc. has a market capitalization of 33.65 million and reported net sales of 0.00 million with a net profit of -28.92 million over the last four quarters. Shareholder's funds are 0.81 million, and total assets amount to 15.50 million.

As of Jun 18, Reviva Pharmaceuticals Holdings, Inc. has a market capitalization of 33.65 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -28.92 million during the same period.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 0.81 million and total assets amounting to 15.50 million.

Read More

What does Reviva Pharmaceuticals Holdings, Inc. do?

22-Jun-2025

Reviva Pharmaceuticals Holdings, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net loss of $6 million and a market cap of $33.65 million. Key metrics include a debt-to-equity ratio of 1.14 and a return on equity of 655.62%.

Overview:<BR>Reviva Pharmaceuticals Holdings, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 33.65 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 1.14<BR>- Return on Equity: 655.62%<BR>- Price to Book: -7.55<BR><BR>Contact Details:<BR>Details: No Company Details Available<BR>Registrar Address: Not available.

Read More

Is Reviva Pharmaceuticals Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Reviva Pharmaceuticals is in a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -76.83% versus the index's 12.22%.

As of 2 September 2025, the technical trend for Reviva Pharmaceuticals Holdings, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The weekly MACD is mildly bullish, but the monthly MACD remains bearish. The moving averages are bearish on a daily basis, and Bollinger Bands indicate a bearish trend in both weekly and monthly time frames. The KST shows a mildly bullish signal weekly, while Dow Theory presents a mildly bearish view weekly and mildly bullish monthly. <BR><BR>In terms of performance, Reviva has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -76.83% versus the S&P 500's 12.22%, and a one-year return of -69.61% compared to 17.14% for the index.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 30 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

10.25

stock-summary
Return on Equity

2,724.52%

stock-summary
Price to Book

-30.40

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-6 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
28.52%
0%
28.52%
6 Months
-27.51%
0%
-27.51%
1 Year
-49.9%
0%
-49.9%
2 Years
-84.58%
0%
-84.58%
3 Years
-83.67%
0%
-83.67%
4 Years
-83.8%
0%
-83.8%
5 Years
-94.45%
0%
-94.45%

Reviva Pharmaceuticals Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Reviva Pharmaceuticals Holdings, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for Reviva Pharmaceuticals Holdings, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The weekly MACD is mildly bullish, but the monthly MACD remains bearish. The moving averages are bearish on a daily basis, and Bollinger Bands indicate a bearish trend in both weekly and monthly time frames. The KST shows a mildly bullish signal weekly, while Dow Theory presents a mildly bearish view weekly and mildly bullish monthly. In terms of performance, Reviva has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -76.83% versus the S&P 500's 12.22%, and a one-year return of -69.61% compared to 17.14% for the index....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-291.95%
EBIT to Interest (avg)
-20.08
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.14
Sales to Capital Employed (avg)
0
Tax Ratio
0.06%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
23.42%
ROCE (avg)
0
ROE (avg)
0.36%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-8.61
EV to EBIT
-1.13
EV to EBITDA
-1.13
EV to Capital Employed
-3.50
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (4.88%)

Foreign Institutions

Held by 17 Foreign Institutions (2.49%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 22.78% vs 36.29% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.10",
          "val2": "-8.10",
          "chgp": "24.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.10",
          "val2": "-7.90",
          "chgp": "22.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 23.92% vs -38.87% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-30.80",
          "val2": "-39.50",
          "chgp": "22.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.70",
          "val2": "-0.20",
          "chgp": "450.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-29.90",
          "val2": "-39.30",
          "chgp": "23.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.10
-8.10
24.69%
Interest
0.00
0.00
Exceptional Items
0.00
0.20
-100.00%
Consolidate Net Profit
-6.10
-7.90
22.78%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 22.78% vs 36.29% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-30.80
-39.50
22.03%
Interest
0.00
0.00
Exceptional Items
0.70
-0.20
450.00%
Consolidate Net Profit
-29.90
-39.30
23.92%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 23.92% vs -38.87% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Reviva Pharmaceuticals Holdings, Inc. stock-summary
stock-summary
Reviva Pharmaceuticals Holdings, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."